Silvia Reni Bortolin Uliana

• Abstract

  The various clinical forms of leishmaniasis are highly prevalent diseases in Brazil. In recent years, the classical, predominantly rural, geographical distribution of the disease has changed and we have witnessed a considerable increase in the number of urban cases. Only a few drugs are available for leishmaniasis treatment and these display several disadvantages such as high cost and tox…

  Evaluation of candidate drugs for the treatment of Leishmaniasis in Brazil, AP.R

• Abstract

  Human leishmaniasis is an endemic disease distributed in tropical and subtropical regions of the world with an estimated 2 million new cases each year. The treatment of all clinical forms of leishmaniasis relies on costly parenteral administered drugs with multiple undesirable effects. Moreover, the first line drugs are becoming ineffective due to the proliferation of resistant parasites.…

  New approaches to combination chemotherapy for human leishmaniasis, AP.R

• Abstract

  The treatment of all clinical forms of leishmaniasis relies on costly parenteral administered drugs with multiple undesirable effects. We have recently described the antileishmanial activity of tamoxifen, a drug already in use for the treatment of breast cancer for over 30 years. Tamoxifen has been shown to be effective in several in vivo experimental models of visceral and cutaneous leis…

  Tamoxifen in the treatment of leishmaniasis: evaluation of efficacy in combination therapy schemes and study of the antileishmanial mechanism of action, AP.R

(Only some records are available in English at this moment)

• Abstract

  Leishmania (Viannia) braziliensis is the main etiological agent of Cutaneous Leishmaniasis in Brazil, where in 2014 approximately 21,000 new cases of the disease were notified. The arsenal available for treatment is limited due to parenteral administration, toxicity, high cost, and emergence of resistance. Miltefosine is the only oral drug approved for the treatment of Cutaneous and Visce…

  Susceptibility to miltefosine in Leishmania (Viannia) braziliensis clinical isolates: phenotypic characterization and investigation of the basis involved in reduced susceptibility to the drug, BP.DD

• Abstract

  Leishmaniasis is caused by more than 20 species of the Leishmania genus resulting in a wide clinical spectrum of diseases distributed worldwide. Visceral leishmaniasis, given its high incidence and mortality, is considered by the World Health Organization as one of the major diseases of our time. Leishmaniasis's chemotherapy relies on a very limited number of drugs, including pentavalent …

  New approaches to circumvent shortcomings of leishmaniasis treatment: design of an in vitro visceral leishmaniasis model based on the organs-on-a-chip technology and testing of strategies to revert antimony resistance, BP.PD

• Abstract

  Protozoan parasites of the Leishmania genus are the etiological agents of leishmaniasis, diseases with diverse clinical presentations. Globally, about 2 million cases of tegumentary and visceral leishmaniasis are diagnosed every year. Only a few drugs are available for the treatment of leishmaniasis in Brazil: meglumine antimoniate, amphotericin B and pentamidine. However, these drugs pre…

  Production of Leishmania amazonensis mutant lines expressing modified luciferases, BP.IC

(Only some records are available in English at this moment)

• Abstract

  The first choice drug for cutaneous leishmaniasis treatment in Brazil, where Leishmania (Viannia) braziliensis is the most prevalent etiological agent, is meglumine antimoniate, administered intravenously for 20 days. Success rates for antimonial therapy can be as low as 50% in some areas. As part of an effort to evaluate whether miltefosine would be applicable to leishmaiasis chemotherap…

  Investigating the role of Ros3 in differential susceptibility of Leishmania to miltefosine using a CRISPR/Cas9 approach, BE.EP.DD

• Abstract

  Leishmaniasis is caused by more than 20 species of the Leishmania genus resulting in a wide clinical spectrum of diseases distributed worldwide. Visceral leishmaniasis, given its high incidence and mortality, is considered by the World Health Organization as one of the major diseases of our time. Leishmaniasis's chemotherapy relies on a very limited number of drugs that presents limitatio…

  New approaches to circumvent shortcomings of leishmaniasis treatment: design of an in vitro visceral leishmaniasis model based on the organs-on-a-chip technology, BE.EP.PD